dexamethasone for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. anti-inflammatoty and immuno-therapy
vs. corticosteroids
vs. dexamethasone
vs. dexamethasone 6mg
vs. Immunosuppressants drugs
vs. anti-interleukin-6
vs. tocilizumab
vs. control
vs. standard of care

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 0

table network network 2

display ongoing demontrated benefit only

popup

Villar, 2020 NCT04325061

dexamethasone vs. control

COVID 19 hospitalized

RECOVERY dexamethasone, 2020 NCT04381936

dexamethasone vs. standard of care

COVID 19 hospitalized

CODEX (Tomazini), 2020 NCT04327401

dexamethasone vs. standard of care

COVID-19 severe or critically

Jamaati, 2021 IRCT20151227025726N1

dexamethasone vs. standard of care

COVID-19 severe or critically

DEXA-COVID19, 2020 NCT04325061

dexamethasone vs. standard of care

COVID-19 severe or critically

Rashad, 2021 NCT04519385

dexamethasone vs. tocilizumab

COVID-19 severe or critically

Naik, 2021

dexamethasone vs. tocilizumab

COVID-19 severe or critically

COVID STEROID 2, 2021 NCT04509973

Dexamethasone 12mg vs. dexamethasone 6mg

COVID-19 severe or critically

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open